Who owns Mersana Therapeutics Inc?
- Ticker: MRSN
- CUSIP Number: 59045l205
Tip: Access positions for across all investors
Analyze quarterly positions in Mersana Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Mersana Therapeutics stock
Who bought or sold Mersana Therapeutics Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Nextech Invest | 483k | $3.7M | 100% | Sep 2025 |
|
| Alamea Verwaltungs GmbH | 430k | $3.3M | 100% | Sep 2025 |
|
| Bain Capital Life Sciences Investors | 347k | $2.7M | 100% | Sep 2025 |
|
| Vanguard Group | 303k | $2.3M | 100% | Sep 2025 |
|
| Schonfeld Strategic Advisors | 274k | $2.1M | 100% | Sep 2025 |
|
| Rock Springs Capital Management | 153k | $1.2M | 100% | Sep 2025 |
|
| Acadian Asset Management | 142k | $1.1M | 100% | Sep 2025 |
|
| Silverarc Capital Management | 134k | $1.0M | 100% | Sep 2025 |
|
| 683 Capital Management | 100k | $776k | 100% | Sep 2025 |
|
| BlackRock | 96k | $747k | 100% | Sep 2025 |
|
| Renaissance Technologies | 89k | $687k | 100% | Sep 2025 |
|
| Millennium Management | 78k | $605k | 100% | Sep 2025 |
|
| 5AM Venture Management | 52k | $405k | 100% | Sep 2025 |
|
| Mackenzie Financial | 48k | $371k | 100% | Sep 2025 |
|
| AQR Capital Management | 47k | $363k | 100% | Sep 2025 |
|
| Geode Capital Management | 42k | $323k | 100% | Sep 2025 |
|
| Two Sigma Advisers | 41k | $315k | 100% | Sep 2025 |
|
| Two Sigma Investments | 31k | $238k | 100% | Sep 2025 |
|
| State Street Corporation | 30k | $232k | 100% | Sep 2025 |
|
| Lion Point Capital | 26k | $200k | 100% | Sep 2025 |
|
| Ieq Capital | 15k | $118k | 100% | Sep 2025 |
|
| DRW Holdings | 14k | $108k | 100% | Sep 2025 |
|
| Voleon Capital Management | 13k | $102k | 100% | Sep 2025 |
|
| UBS Group | 8.6k | $67k | 100% | Sep 2025 |
|
| Jpmorgan Chase & Co | 6.1k | $47k | 100% | Sep 2025 |
|
| FMR | 4.9k | $38k | 100% | Sep 2025 |
|
| CWM | 2.9k | $22k | 100% | Sep 2025 |
|
| Tower Research Capital | 1.6k | $12k | 100% | Sep 2025 |
|
| Wells Fargo & Company | 1.2k | $9.6k | 100% | Sep 2025 |
|
| Group One Trading | 961.00 | $7.5k | 100% | Sep 2025 |
|
| China Universal Asset Management | 875.00 | $6.8k | 100% | Sep 2025 |
|
| Royal Bank of Canada | 692.00 | $5.0k | 100% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 531.00 | $4.1k | 100% | Sep 2025 |
|
| Barclays | 198.00 | $1.5k | 100% | Sep 2025 |
|
| Mirae Asset Global Investments | 193.00 | $1.5k | 100% | Sep 2025 |
|
| SRS Capital Advisors | 157.00 | $1.2k | 100% | Sep 2025 |
|
| Advisor Group Holdings | 103.00 | $755.000300 | 100% | Sep 2025 |
|
| Gf Fund Management | 94.00 | $728.998200 | 100% | Sep 2025 |
|
| SBI Securities | 54.00 | $419.002200 | -96% | Sep 2025 |
|
| Huntington National Bank | 32.00 | $248.000000 | 100% | Sep 2025 |
|
| IFP Advisors | 5.00 | $39.000000 | 100% | Sep 2025 |
|
| Danske Bank A/s | 1.00 | $8.000000 | 100% | Sep 2025 |
|
Who sold out of Mersana Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Marshall Wace | Jun 2025 | 227k | $68k |